Lung Cancer Liquid Biopsy Market Size, Share, Growth, and Industry Analysis, By Type (CTCs, CtDNA, Exosomes and RNA, Others), By Application (Clinics, Hospitals, Physicians' Office Laboratories), Regional Insights and Forecast to 2035

Lung Cancer Liquid Biopsy Market Overview

The global Lung Cancer Liquid Biopsy Market is forecast to expand from USD 630.69 million in 2026 to USD 718.99 million in 2027, and is expected to reach USD 2050.98 million by 2035, growing at a CAGR of 14% over the forecast period.

The Lung Cancer Liquid Biopsy Market is experiencing significant global growth due to advancements in non-invasive cancer diagnostics, increasing cancer prevalence, and precision oncology developments. Over 2.3 million new lung cancer cases were reported worldwide in 2023, with 85% classified as non-small cell lung cancer (NSCLC). Approximately 65% of lung cancer patients undergo biomarker testing for targeted therapy decisions, of which 38% rely on liquid biopsy methods. Over 420 companies are actively engaged in liquid biopsy technology development, with approximately 120 focusing solely on lung cancer diagnostics. The growing demand for early cancer detection and real-time monitoring is driving adoption across healthcare systems globally.

In the United States, lung cancer accounts for nearly 21% of total cancer-related deaths annually, with approximately 230,000 new cases diagnosed in 2023. The adoption of liquid biopsy in lung cancer diagnostics has increased by 34% since 2021, largely due to improved FDA approvals of companion diagnostic assays. Over 45% of oncologists in the U.S. utilize liquid biopsy as a first-line diagnostic tool for advanced NSCLC patients. In addition, about 68,000 patients in the U.S. are monitored using circulating tumor DNA (ctDNA)-based platforms for disease progression. The American healthcare system has integrated over 300 certified liquid biopsy laboratories, enabling rapid genomic profiling and real-time treatment optimization.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Around 62% growth in adoption is driven by increased demand for non-invasive cancer diagnostics and real-time genetic mutation detection in lung cancer management.
• Major Market Restraint: Nearly 44% of market participants face cost-related challenges associated with biomarker validation and limited test standardization across clinical applications.
• Emerging Trends: Approximately 53% of new developments focus on next-generation sequencing (NGS)-based liquid biopsy platforms for comprehensive genomic profiling.
• Regional Leadership: North America leads with 39% of the global share, driven by advanced healthcare infrastructure and accelerated clinical trial adoption.
• Competitive Landscape: Top 15 companies account for 69% of the global market, with expanding collaborations between diagnostics and pharmaceutical firms.
• Market Segmentation: About 47% of demand arises from circulating tumor DNA (ctDNA) assays, followed by circulating tumor cells (CTCs) at 31% and exosome-based platforms at 22%.
• Recent Development: More than 55 clinical validation studies on liquid biopsy biomarkers were initiated globally between 2022 and 2024, marking a 29% rise in R&D activity.

Lung Cancer Liquid Biopsy Market Latest Trends

The Lung Cancer Liquid Biopsy Market is witnessing rapid technological advancements as healthcare providers increasingly adopt minimally invasive diagnostic methods for early cancer detection and treatment monitoring. The growing use of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and cell-free DNA (cfDNA) analysis is significantly improving the accuracy of identifying genetic mutations associated with lung cancer. Integration of next-generation sequencing (NGS), artificial intelligence, and advanced bioinformatics platforms is enabling faster genomic profiling, supporting personalized treatment decisions while reducing the need for repeated tissue biopsies.

Another major trend shaping the market is the increasing adoption of liquid biopsy for companion diagnostics, therapy selection, and real-time disease monitoring. Pharmaceutical companies and diagnostic manufacturers are expanding collaborations to develop highly sensitive multi-gene assays capable of detecting multiple biomarkers from a single blood sample. Continuous improvements in assay sensitivity, automation, and laboratory workflow efficiency are making liquid biopsy more accessible across hospitals, diagnostic laboratories, and cancer research centers. Growing investments in precision oncology, clinical validation studies, and regulatory approvals are further accelerating the global adoption of lung cancer liquid biopsy technologies.

Lung Cancer Liquid Biopsy Market Dynamics

DRIVER

"Increasing global lung cancer prevalence and demand for non-invasive diagnostics"

The increasing incidence of lung cancer worldwide continues to accelerate demand for advanced liquid biopsy technologies that enable early diagnosis without invasive surgical procedures. Healthcare providers are increasingly adopting liquid biopsy because it allows repeated sample collection, supports continuous disease monitoring, and helps identify actionable genetic mutations with greater patient comfort. The growing focus on early-stage detection has significantly strengthened the adoption of blood-based molecular diagnostic testing across oncology centers.

The expansion of precision oncology programs has further increased the clinical importance of liquid biopsy in treatment planning and therapeutic monitoring. Advanced technologies capable of detecting EGFR, ALK, KRAS, and other clinically relevant mutations provide physicians with valuable real-time genomic information throughout the treatment cycle. As personalized medicine continues expanding globally, demand for rapid, accurate, and minimally invasive diagnostic solutions is expected to remain strong.

RESTRAINT

"High testing costs and limited assay standardization"

The high cost associated with advanced liquid biopsy testing continues to limit widespread adoption, particularly in developing economies where healthcare budgets remain constrained. Expensive sequencing platforms, specialized laboratory infrastructure, and skilled molecular diagnostics personnel increase overall testing expenses, making routine clinical implementation difficult for many healthcare institutions.

Another major restraint involves inconsistent assay standardization across laboratories and diagnostic platforms. Differences in sample collection methods, sequencing technologies, and result interpretation can produce variations in clinical outcomes. Limited reimbursement policies in several healthcare systems further restrict patient access, slowing broader commercialization despite growing clinical acceptance.

OPPORTUNITY

"Expansion of personalized medicine and targeted therapies"

The rapid expansion of personalized medicine is creating substantial opportunities for the Lung Cancer Liquid Biopsy Market. Healthcare providers increasingly rely on genomic profiling to identify patients eligible for targeted therapies, enabling more precise treatment decisions while reducing unnecessary chemotherapy exposure. Liquid biopsy plays an increasingly important role by providing continuous molecular information throughout disease progression.

Growing pharmaceutical investment in biomarker-driven drug development is further strengthening market opportunities. Companion diagnostic testing, next-generation sequencing platforms, and AI-supported genomic interpretation continue improving diagnostic efficiency and treatment selection. These developments are expected to increase adoption across hospitals, cancer centers, and research institutions worldwide.

CHALLENGE

"Regulatory hurdles and data management complexities"

Stringent regulatory approval processes continue to present significant challenges for manufacturers introducing new liquid biopsy technologies. Clinical validation requirements, extensive performance studies, and evolving regulatory standards often extend commercialization timelines while increasing development costs. Meeting varying regional regulatory requirements also complicates international product expansion strategies.

Managing rapidly growing genomic datasets presents another major operational challenge for healthcare providers. Advanced sequencing technologies generate enormous volumes of molecular information requiring secure storage, rapid analysis, and accurate interpretation. Limited availability of experienced molecular pathologists and bioinformatics professionals further complicates efficient implementation of advanced liquid biopsy platforms.

Why is Demand Increasing for the Lung Cancer Liquid Biopsy Industry?

Demand for the Lung Cancer Liquid Biopsy Industry is increasing due to the growing prevalence of lung cancer and the rising need for accurate, minimally invasive diagnostic methods. Liquid biopsy enables early detection, continuous disease monitoring, and real-time identification of genetic mutations without the need for repeated tissue biopsies. The increasing adoption of precision medicine, targeted therapies, and companion diagnostics has further accelerated demand across hospitals, diagnostic laboratories, and oncology centers. Continuous technological advancements in next-generation sequencing (NGS), circulating tumor DNA (ctDNA) analysis, and AI-powered genomic profiling are also improving diagnostic accuracy and expanding clinical applications worldwide.

Lung Cancer Liquid Biopsy Market Segmentation

The Lung Cancer Liquid Biopsy Market is segmented by type and application, enabling a detailed understanding of its technological and clinical distribution. By type, the market is divided into Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Exosomes and RNA, and Others. Each segment contributes distinctly to diagnostic precision, treatment selection, and disease monitoring. By application, the market includes Clinics, Hospitals, and Physicians’ Office Laboratories, each representing unique implementation levels of liquid biopsy technology. This segmentation highlights the structural adoption and technological penetration across healthcare ecosystems worldwide, providing a clear insight into the Lung Cancer Liquid Biopsy Market Size, Market Share, and Market Growth potential.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Circulating Tumor Cells (CTCs): Circulating Tumor Cells (CTCs) account for 28% of the global Lung Cancer Liquid Biopsy Market and remain an important biomarker for monitoring tumor progression and metastatic potential. These assays provide valuable information regarding treatment response while supporting clinicians in evaluating disease recurrence through minimally invasive blood sampling procedures.

Continuous innovation in cell isolation technologies, microfluidics, and immunomagnetic separation has significantly improved CTC detection performance. Integration with digital imaging and artificial intelligence is enhancing analytical accuracy while enabling more efficient monitoring throughout personalized cancer treatment programs.

Circulating Tumor DNA (ctDNA): Circulating Tumor DNA (ctDNA) represents 45% of the market and has become the leading technology for genomic profiling in lung cancer diagnostics. The ability to identify clinically relevant mutations through blood samples supports rapid treatment selection while allowing continuous monitoring of therapy effectiveness and disease progression.

Ongoing advances in next-generation sequencing and digital PCR technologies continue improving ctDNA sensitivity and mutation detection accuracy. Increasing integration into precision oncology programs, companion diagnostics, and targeted therapy selection is expected to sustain strong demand across global healthcare systems.

Exosomes and RNA: Exosomes and RNA-based liquid biopsy technologies account for 20% of the global market and are gaining importance due to their ability to capture comprehensive molecular information from tumor-derived extracellular vesicles. These biomarkers provide valuable insights into gene expression, disease progression, and therapeutic response.

Growing research into RNA sequencing, exosomal biomarkers, and multi-omics technologies continues expanding their diagnostic applications. Improvements in analytical platforms are enabling earlier detection while supporting more accurate personalized treatment strategies for lung cancer patients.

Others: The Others segment contributes 7% of the Lung Cancer Liquid Biopsy Market and includes methylation biomarkers, proteomic assays, and other emerging molecular diagnostic technologies. These approaches complement existing liquid biopsy methods by providing additional biological information for comprehensive cancer assessment.

Continuous innovation in epigenetic analysis and hybrid biomarker platforms is improving diagnostic precision while supporting ongoing oncology research. Increasing clinical validation studies are expected to broaden commercial adoption over the coming years.

BY APPLICATION

Clinics: Clinics represent 29% of the Lung Cancer Liquid Biopsy Market as decentralized diagnostic services become increasingly available for early cancer detection and treatment monitoring. Liquid biopsy enables faster clinical decision-making while improving patient convenience through minimally invasive testing procedures.

The expansion of outpatient oncology services and point-of-care molecular diagnostics continues strengthening demand within clinical settings. Digital reporting platforms and telemedicine integration further improve accessibility and operational efficiency for physicians and patients.

Hospitals: Hospitals account for 55% of the global market and remain the largest end-users of lung cancer liquid biopsy technologies. Comprehensive oncology departments utilize advanced genomic testing for diagnosis, treatment planning, therapeutic monitoring, and disease surveillance across multiple stages of cancer management.

Continuous investment in precision medicine programs, molecular pathology laboratories, and integrated sequencing platforms is strengthening hospital adoption. Collaboration with pharmaceutical companies and research organizations further supports innovation in personalized oncology diagnostics.

Physicians' Office Laboratories: Physicians' Office Laboratories hold 16% of the market by providing convenient molecular diagnostic services closer to patients. These facilities reduce testing turnaround times while enabling oncologists to monitor treatment response more efficiently through routine blood sampling.

Advancements in compact diagnostic platforms, automated sample processing, and digital reporting systems continue improving laboratory productivity. Growing demand for decentralized precision medicine services is expected to further expand adoption across physician-led diagnostic facilities.

Which Segment is Growing Faster?

The Circulating Tumor DNA (ctDNA) segment is the fastest-growing segment in the Lung Cancer Liquid Biopsy Market, accounting for 45% of the global market share. Its rapid growth is driven by high sensitivity in detecting clinically relevant mutations such as EGFR, ALK, and KRAS, enabling personalized treatment selection and real-time monitoring of disease progression. Increasing integration of ctDNA assays into precision oncology programs, companion diagnostics, and next-generation sequencing platforms continues to strengthen its adoption across healthcare systems.

Lung Cancer Liquid Biopsy Market Regional Outlook

North America dominates the Lung Cancer Liquid Biopsy Market due to advanced healthcare infrastructure, early technology adoption, and high investment in precision oncology research across the U.S. and Canada.Europe remains a major market, supported by favorable regulatory approvals, integration of liquid biopsy in cancer management, and ongoing national screening programs.Asia-Pacific exhibits rapid market expansion driven by growing lung cancer incidence, supportive government initiatives, and strong presence of diagnostic laboratories in China, Japan, and India.The Middle East & Africa region is emerging as a promising market with expanding healthcare systems, increasing cancer awareness, and rising investments in biomarker-based oncology diagnostics.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America holds 41% of the global Lung Cancer Liquid Biopsy Market due to its advanced healthcare infrastructure, extensive precision oncology programs, and widespread adoption of genomic diagnostics. Strong research funding, favorable reimbursement policies, and leading biotechnology companies continue supporting regional market expansion.

Continuous investment in clinical trials, biomarker discovery, and AI-powered genomic analysis strengthens North America's leadership position. High awareness among healthcare providers and rapid adoption of personalized cancer therapies continue driving sustained market growth.

Europe

Europe represents 29% of the global market, supported by well-developed healthcare systems, favorable regulatory frameworks, and expanding national cancer screening initiatives. Countries across the region continue increasing investments in molecular diagnostics to improve early detection and personalized treatment outcomes.

Growing collaboration between research institutions, hospitals, and biotechnology companies is accelerating technological innovation. Increasing integration of liquid biopsy into routine oncology practice is expected to further strengthen regional market development.

Asia-Pacific

Asia-Pacific accounts for 22% of the Lung Cancer Liquid Biopsy Market and continues to experience rapid expansion due to rising cancer incidence, healthcare modernization, and increasing government support for precision medicine. Growing investments in molecular diagnostic laboratories are improving access to advanced testing services.

Rapid industrial development, expanding biotechnology sectors, and increasing adoption of next-generation sequencing technologies continue supporting market growth. Strong demand from China, Japan, India, and South Korea is expected to drive future regional expansion.

Middle East & Africa

Middle East & Africa contribute 8% of the global market as healthcare infrastructure continues improving across several countries. Increasing awareness of early cancer diagnosis and expanding oncology services are supporting gradual adoption of liquid biopsy technologies throughout the region.

Government investment in cancer treatment facilities, international collaborations, and modernization of diagnostic laboratories continue creating new opportunities. Growing emphasis on precision medicine and improved healthcare accessibility is expected to support long-term market development.

Which Region Holds the Largest Market Share?

North America holds the largest share of the global Lung Cancer Liquid Biopsy Market with 41% of the total market. The region's leadership is supported by advanced healthcare infrastructure, widespread adoption of precision oncology, strong clinical research activities, favorable reimbursement policies, and rapid regulatory approvals for liquid biopsy technologies. High investment in genomic diagnostics, extensive use of companion diagnostic testing, and the presence of leading biotechnology companies continue to drive market expansion across the United States and Canada.

List of Top Lung Cancer Liquid Biopsy Market Companies

• Biocept
• Exosome Diagnostics
• F. Hoffmann-La Roche
• Qiagen
• Accuragen
• Agena Bioscience
• Bard1
• BGI

Top Two Companies with the Highest Market Share

• F. Hoffmann-La Roche: Holds 15% of the global market share with more than 220,000 liquid biopsy tests deployed annually across 75 countries using its validated oncology assay portfolio.
• Qiagen: Accounts for 12% share, offering over 150,000 annual lung cancer liquid biopsy tests with high-precision ctDNA extraction kits and integration in 300 global hospital systems.

Investment Analysis and Opportunities

Investment activity in the Lung Cancer Liquid Biopsy Market continues to accelerate as biotechnology companies, diagnostic manufacturers, and healthcare organizations expand precision oncology capabilities. Significant funding is being directed toward next-generation sequencing, artificial intelligence, multi-gene biomarker analysis, and automated laboratory platforms that improve diagnostic accuracy while reducing testing time. Strategic partnerships between pharmaceutical companies and molecular diagnostics developers are further strengthening commercialization opportunities.

Emerging economies present considerable investment potential as governments expand cancer screening programs and modernize healthcare infrastructure. Increasing demand for affordable liquid biopsy solutions, decentralized testing platforms, and companion diagnostics is encouraging companies to invest in localized manufacturing and clinical validation programs. Continued innovation in personalized medicine is expected to generate strong long-term growth opportunities across global oncology diagnostics.

New Product Development

Manufacturers are focusing on developing advanced liquid biopsy platforms with higher analytical sensitivity, faster processing speeds, and broader mutation detection capabilities. New product innovations combine next-generation sequencing, digital PCR, artificial intelligence, and automated workflow management to deliver highly accurate genomic profiling while minimizing laboratory complexity. These technologies support earlier diagnosis and more personalized treatment planning.

Companies are also introducing integrated multi-biomarker platforms capable of simultaneously analyzing ctDNA, CTCs, RNA, exosomes, and methylation markers within a single testing workflow. Continuous improvements in assay automation, cloud-based analytics, and bioinformatics software are enhancing laboratory productivity while reducing operational costs across hospitals, diagnostic laboratories, and cancer research centers.

Five Recent Developments 

• In 2023, Qiagen launched the QIAseq Lung Cancer Liquid Biopsy Kit with enhanced multiplexing sensitivity up to 99.5%.
• F. Hoffmann-La Roche introduced a ctDNA-based lung cancer monitoring system in 2024 for clinical oncology trials.
• Biocept announced a 2024 collaboration with a global cancer institute to validate CTC detection accuracy in NSCLC.
• Exosome Diagnostics launched an RNA-based exosome lung cancer assay with 20% improved sensitivity in 2025.
• BGI unveiled a multi-region NGS-based lung cancer liquid biopsy platform for clinical applications in Asia-Pacific in 2025.

Report Coverage of Lung Cancer Liquid Biopsy Market

The Lung Cancer Liquid Biopsy Market Report provides comprehensive analysis of industry trends, technological advancements, competitive developments, market dynamics, and regional growth opportunities. The study evaluates segmentation by biomarker type, application, and geography while examining technological innovation, clinical adoption, regulatory developments, and competitive positioning across the global oncology diagnostics landscape.

The report also analyzes leading manufacturers, strategic partnerships, product launches, investment activities, research collaborations, and emerging precision medicine trends influencing market expansion. Detailed assessment of healthcare infrastructure, reimbursement policies, laboratory automation, genomic technologies, and future business opportunities enables manufacturers, investors, healthcare providers, and policymakers to develop effective long-term growth strategies within the global Lung Cancer Liquid Biopsy Market.

Lung Cancer Liquid Biopsy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 630.69 Million in 2026
Market Size Value By	USD 2050.98 Million by 2035
Growth Rate	CAGR of 14% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : CTCs CtDNA Exosomes and RNA Others By Application : Clinics Hospitals Physicians' Office Laboratories
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample